

18. Thormann A, Sřrensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. *Neurology*. 2017;89(16):1668-1675.
19. Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy initiation and choice in MS. *Mult Scler Relat Disord*. 2016;8:146-152.
20. Magyari M, Sřrensen PS. Comorbidity in Multiple Sclerosis. *Front Neurol*. 2020;11:851.
21. Geraldes R, Ciccirelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. *Pract Neurol*. 2018;18(6):441-452.
22. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. *Neurology*. 2010;74(13):1041-1047.
23. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. *Ann Neurol*. 2012;72(2):234-240.
24. Feinstein A, Magalhaes S, Richard JF, et al. The link between multiple sclerosis and depression. *Nat Rev Neurol*. 2014;10(9):507-517.
25. Tetley P, Simpson S Jr, Taylor BV, et al. An approach to studying co-occurring autoimmune diseases in multiple sclerosis. *Mult Scler Relat Disord*. 2014;3(3):254-265.
26. Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. *JAMA Neurol*. 2020;77(2):184-191.
27. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. *Nat Rev Dis Primers*. 2022;8:48.
28. Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing MS. *Ann Neurol*. 2019;85(5):653-666.
29. Braley TJ, Segal BM. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. *J Clin Sleep Med*. 2014;10(2):155-162.
30. Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: population-based Epidemiology of Vascular Ageing-MRI study. *BMJ*. 2011;342:c7357.
31. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in MS. *JAMA Neurol*. 2019;76(5):536-541.
32. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol*. 2020;19(4):307-316.
33. Selmaj K, Cree BAC, Barnett M, et al. Multiple sclerosis: time for early treatment with high-efficacy agents. *J Neurol*. 2024;271(1):105-115.
34. Zeposia (ozanimod) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: [https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf).
35. Ocrevus (ocrelizumab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: [https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf).
36. Kesimpta (ofatumumab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: [https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/kesimpta-epar-product-information_en.pdf).
37. Briumvi (ublituximab) – Summary of Product Characteristics (SmPC) [Internet]. [cited 2025-08-08]. European Medicines Agency. Available from: [https://www.ema.europa.eu/en/documents/product-information/briumvi-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/briumvi-epar-product-information_en.pdf).
38. Brummer T, Ruck T, Meuth SG, et al. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. *Ther Adv Neurol Disord* 2021;14:17562864211035542.
39. Konen FF, Witte T, Ernst D, et al. Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis. *Neurol Res Pract* 2025;7(1):48.
40. Rejdak K, Szklemer S, Korhut A, et al. Cladribine in myasthenia gravis: a pilot open-label study. *Eur J Neurol*. 2020;27(3):586-589.
41. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) [Internet]. [cited 2025-08-11]. Merck Healthcare KgaA. Available from: <https://clinicaltrials.gov/study/NCT06463587/>.
42. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2005;353:1912-1925.
43. Targan SR, Feagan BG, Fedorak RN, et al. ENCORE trial – natalizumab for active Crohn's disease. *Gastroenterology*. 2007;132(5):1672-1683.
44. Delcoigne B, Kopp TI, Arkema EV, et al. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. *RMD Open*. 2023;9(1):e002924.
45. Li L, Aviña-Zubieta JA, Bernstein CN, et al. Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor  $\alpha$  in 4 Canadian Provinces: A Population-Based Study. *Neurology*. 2023;100(6):e558-e567.
46. Konen FF, Möhn N, Witte T, et al. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. *Autoimmun Rev*. 2023;22(5):103312.
47. Mason A, Fragapane L, Toledo-Nieves Z, et al. Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies for the Treatment of Migraines in Individuals With Multiple Sclerosis. *Int J MS Care* 2024;26(3):104-107.
48. Nociti V, Romozzi M, Annovazzi P, et al. Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies. *J Neurol Sci*. 2025;469:123392.
49. Di Tullio F, Odorici G, Lasagni C, et al. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. *Dermatol Ther*. 2020;33(6):e13943.
50. Eksin MA, Erden A, Güven SC, et al. Secukinumab in the treatment of psoriatic arthritis or ankylosing spondylarthritis with multiple sclerosis: a case series with literature review. *Immunotherapy*. 2022;14(6):401-408.
51. Elgenidy A, Elkady A, El-Dahshan M, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 patients. *Front Neurol* 2024;15:1380654.
52. Kolčava J, Lasotová N, Vlčková E, et al. Validation of Dysphagia in Multiple Sclerosis questionnaire – Czech version of DYMUS. *Čes Slov Neurol Neurochir* 2020;83/116(3):285-290.
53. Montalban X, Gold R, Thompson AJ, et al.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. *Mult Scler*. 2018;24(2):96-120.
54. Thakolwiboon S, Mills EA, Yang J, et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. *Front Aging*. 2023;4:1234572.
55. van der Walt A, Strijbis EMM, Bridge, F et al. Advancing multiple sclerosis management in older adults. *Nat Rev Neurol*. 2025;21:432-448.
56. Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. *Lancet Neurol*. 2023;22(7):568-577.
57. Coerver EME, Fung WH, de Beukelaar J, et al. Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial. *JAMA Neurol*. 2025;82(2):123-131.
58. Lee S, Scheu R, Mateen FJ. Adults 55 Years and Older with Multiple Sclerosis (MS) Treated with Ocrelizumab: Characteristics and Outcomes Over More Than 13,000 Person-Months (Abstract P10-1.013). *Neurology*. 2025;104(7):Suppl1.